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Biological therapy and international travel: A questionnaire 
survey among Danish patients with rheumatic disease
Introduction
For more than 50 years, the treatment of autoimmune inflammatory rheumatic diseases (AIRD) has 
been based on use of steroids and disease-modifying antirheumatic drugs (DMARDs). The introduc-
tion of biologics since 1999 has revolutionized the therapeutic approach, particularly in patients 
with inadequate response to standard DMARDs. As a result, patients with rheumatoid arthritis, pso-
riatic arthritis, and spondylarthropathies today experience an improved daily functional level and 
quality of life, which allows them to work and also to travel for different purposes, including holiday, 
family visit, or business (1). However, different concerns and challenges related to chronic arthritis 
itself or to the treatment may prompt the patients to avoid traveling or change an otherwise pre-
ferred destination.
The number of international travelers has increased steadily in the past decades (2). Patients with 
underlying chronic diseases are also traveling more extensively in these years. In a 2014 Danish 
study, as many as 92% of patients with human immunodeficiency virus (HIV) infection reported 
travel activity outside Denmark despite different potential obstacles, such as HIV status on entry 
to certain countries, immune-deficiency-associated risk of infections, and the need of hand-car-
ried medicine across the borders (3). Patients with arthritis may, in a similar manner as those with 
HIV, meet different obstacles when traveling, in particular to the part of transport and storage of 
subcutaneous biologics, which are administered by self-injections with intervals between twice 
weekly and once monthly. The biologics must be kept at a specific temperature range of 2°C-8°C, 
which requires a cooling box when traveling. The cooling element may cause problems for patients 
during the hand luggage scanning procedure if the liquid content exceeds the 100 mL limit, as 
stated in the international airport security regulations. Increased susceptibility to infections owing 
to the treatment with biologics may constitute another concern for the patients with arthritis when 
planning a travel arrangement (4).
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Abstract
Objective: To describe travel activities, preparations, and health problems encountered by patients with 
arthritis receiving biological therapy.
Methods: A travel survey was conducted in a Danish rheumatology outpatient clinic by distribution of 
a semistructured questionnaire to 300 consecutive patients with arthritis. 
Results: Among the 273 (91%) patients returning the questionnaire, a history of traveling outside Den-
mark was reported by 203 (74%) respondents and outside Europe by 92 (34%). In 81% of the patients, 
travel activities had not decreased after the initiation of biological treatment. However, 24% reported 
that they had become more cautious regarding the choice of travel destination. Pre-travel advice was 
sought by less than one-third of the patients, whereas travel insurance was taken out by 86%, but 
only half of them had disclosed information about the biological treatment. Treatment was discon-
tinued temporarily while traveling in 26% of patients on subcutaneous biologics. The main reason for 
discontinuation was concern about transport and storage of medicine. Only 6% of the travelers had 
experienced health problems, which were of only minor importance.
Conclusion: Treatment with biologics seems not to have any major influence on international travel 
activity among Danish patients with arthritis. Health problems when traveling were of minor impor-
tance. However, pre-travel advice issues, including treatment compliance, transport of medicine, and 
insurance coverage, need to be addressed proactively by the outpatient clinic staff as part of patient 
consultation.
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Many countries are issuing recommendations 
to travelers regarding vaccinations prior to en-
try. The responses of vaccinations in patients 
with AIRD may be attenuated by the patient’s 
biologic therapy, resulting in reduced vaccine 
effectiveness and protection. Moreover, there 
is also a potential risk of developing an active 
infection or severe adverse reactions with live 
virus or bacteria following vaccination, such 
as yellow fever (5-7). For this reason, specific 
recommendations have been incorporated for 
immunocompromised patients, such as pa-
tients with arthritis receiving biological treat-
ment (8-10).
In this study, we aimed to assess the report-
ed travel activities and preparations, such as 
pre-travel advice and travel insurance, in a 
questionnaire among Danish patients with ar-
thritis treated with biologics. Health problems 
encountered during the travel were also ad-
dressed in the questionnaire.
Methods
This study was carried out in the rheumatology 
outpatient clinic at a Danish regional hospital 
during a 10-month period from March 2017 to 
December 2017.
More than 1,900 patients with rheumatoid 
arthritis, psoriatic arthritis, juvenile arthritis, or 
spondylarthropathy were followed up in the 
clinic, and 400 of those patients were treated 
with biologics. Patients were registered in the 
National Rheumatology Database in Den-
mark. 
Treatment was provided free of charge to the 
patients. Infusions with biologics were given in 
the clinic with intervals of 6-45 weeks depend-
ing on the specific type of biological drug. 
Self-administered subcutaneous biologics are 
handed out as single-use prefilled syringes or 
pens for 2 months’ consumption. 
A total of 300 consecutive patients with ar-
thritis receiving biological treatment were in-
vited to participate in this study. A semistruc-
tured questionnaire was handed out to each 
study participant. The questionnaire was 
developed with inspiration from a question-
naire being developed and validated in con-
junction with a similar travel survey among 
patients with HIV (3). This group of patients 
with HIV resembles those with rheumatic dis-
ease receiving biologics by having a chronic 
condition of underlying immunodeficiency. 
The questionnaire included 37 items within 
the following 7 main categories: socio-de-
mographic data, treatment prior and during 
travel, history of travel, health insurance 
assignment, pre-travel advice seeking, and 
travel-related health issues. The survey was 
conducted using a cross-sectional design. 
The respondents were anonymous, but it was 
ensured by study participant registration that 
each respondent completed only one unique 
questionnaire. 
This study was reported to the Danish Data 
Protection Agency (2008-58-0028). The region-
al committee of ethics did not require approval 
of this study. A written consent was obtained 
from all the participants.
Statistical analysis 
Statistical analysis was performed using the 
Windows version of Microsoft Office Access 
database management system 2010; for pie 
chart analysis, the Microsoft Office World 2013 
(Redmond, Washington, USA) was used. Cat-
egorical data were compared using the Chi-
square test.
Results 
Among the 300 patients, who were invited 
for this study, 273 (91%) returned the com-
pleted questionnaire (Figure 1). Median age 
of the respondents was 57 years (range, 18-
81 years). 
Travel activity
Travel outside Denmark after the initiation 
of biological treatment was reported by 203 
(74%) patients; among these, 111 (55%) pa-
tients reported travel in Europe only, and 92 
(45%) patients reported additional travel in 
other countries outside Europe (Figure 1). 
More than one-third (36%) of the 203 patients 
reported that the most recent travel had a du-
ration of less than 1 week, while the remaining 
two-thirds reported a duration of more than 1 
week. Figure 2 shows the distribution of trav-
Main Points
• Majority of Danish patients with arthritis 
continue the travel activity level after the 
onset of subcutaneous or intravenous 
biological treatment of their rheumatic 
disease.
• Less than one-third of this group of pa-
tients seek pre-travel advice; however, 
the informants expressed concerns re-
garding the potential implications of bi-
ological treatment, including travel im-
munization and insurance precautions, 
in addition to logistical challenges and 
customs regulations regarding the trans-
port of hand-carried medicine across in-
ternational borders requiring cold chain 
storage facilities.
• Treatment with subcutaneously admin-
istered biologics had been discontinued 
in one-quarter of the patients when trav-
eling.
• A very small proportion of patients have 
experienced health-related problems in 
conjunction with travel, and those prob-
lems were only of minor importance. 
Figure 1. Flowchart showing enrollment of study participants according to travel history.
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el destinations and purposes among the 92 
patients with a travel history outside Europe. 
The most popular travel destination was Asia/
South East, and vacation was the most com-
mon travel purpose.
There was no difference in gender or age be-
tween the patients with a travel history com-
pared to those without (Table 1). Among the 
203 patients reporting a travel history outside 
Denmark, 139 (68%) had the biological drug 
administered by subcutaneous route and 43 
(21%) by intravenous route, whereas 21 (11%) 
patients did not provide this information in 
the questionnaire. Among the 70 (26%) re-
spondents, who did not report travel activities 
outside Denmark, the distribution of biologics 
was different from the group of travelers in 
favor of a higher prevalence of intravenously 
administered biologics as opposed to subcuta-
neously administered biologics (p<0.05 by the 
Chi-square test). 
Compared to the travel status before versus 
after the initiation of biological treatment, 200 
(73%) patients reported no changes in activi-
ties after initiation, whereas 42 (15%) patients 
reported less travel activities, and 21 (8%) pa-
tients reported more travel activities (Table 2). 
Moreover, 183 (67%) patients reported that 
neither the chronic arthritis disease nor the 
medical treatment had any influence on the 
decision to travel abroad. However, this was 
the case for 57 (21%) patients. 
Travel preparations
Pre-travel health advice had been sought 
by 52 (26%) of the 203 patients with a trav-
el history (Table 3). Family practitioner, Inter-
net, and the rheumatology outpatient clinic 
were reported as the most frequent sources 
for provision of pre-travel advice. However, 
travel medicine specialist and vaccination 
clinics were also consulted to some extent. 
One-third (35%) of the patients, who sought 
pre-travel health advice, did not inform 
the advisor about the biological treatment; 
among these, 72% (n=18) stated they did 
not think it was important to share this infor-
mation. Travel insurance coverage had been 
taken out by 174 (86%) patients, but only 72 
(41%) of these patients had disclosed to the 
insurance company that they were receiving 
biological treatment.
Compliance to biological treatment 
Among the 139 travelers receiving sub-
cutaneous biological treatment, 86 (62%) 
reported continuation of the treatment 
during travel, whereas 42 (30%) patients had 
decided to discontinue the treatment be-
Figure 2. a, b. Distributions of travel destinations (a) and travel purposes (b) among the 92 pa-
tients with a travel history outside Europe.
a
b
Table 1. Patient demographic and biologic administration characteristics in accordance with 
travel history.
                                                 Travel history
 Total respondents Yes No
 N=273 n=203 (74%) n=70 (26%)
Gender, n (%)   
Men 127 (47) 95 (46) 32 (46)
Women 146 (53) 110 (53) 36 (51)
Median age, years (range) 57 (18-81) 57 (17-81) 55 (25-81)
Administration route, n (%)   
Subcutaneous 174 (64) 139 (68) 35 (50)*
Infusion 75 (27) 43 (21) 32 (46)*
Not reported 24 (9) 21(11) 3 (4)
*Chi-Square test: p<0.05.
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fore travel departure owing to the concern 
about legal aspects of carrying the medi-
cine on entry to another country. Logistical 
obstacles in handling the medicine when 
traveling were also reported as a reason for 
discontinuation. Another 11 (8%) travelers 
reported that they had discontinued the 
treatment when traveling, making a total of 
53 (38%) patients pausing their subcutane-
ous biological treatment. Two-thirds (71%) 
of the 42 travelers, who stopped taking the 
medicine before the travel departure, did 
not consult their rheumatologist about this 
decision (Table 4).
Health problems 
A total of 13 (6%) patients reported health 
problems during the most recent travel. All 
the health problems were of minor clinical im-
portance. Diarrhea (n=5) was the most preva-
lent health problem followed by aggravation/
activation in rheumatology illness (n=3), fever 
(n=2), and other causes (n=2). 
Discussion
This questionnaire study with a response 
rate of 91% has shown that Danish patients 
with arthritis treated using biologics travel 
frequently to other European countries and 
out of Europe as well. In majority of the pa-
tients, travel activities had remained at the 
same level, and even increased in a propor-
tion of them after the initiation of biological 
treatment. Moreover, it was also shown that 
patients with arthritis receiving biological 
treatment rarely encounter health problems 
when traveling, and if so, the problems are 
only of minor importance and not related 
to the chronic arthritis disease. Only 6% of 
patients had experienced health problems 
when traveling, which is in contrast to the 
figure of plus 50% reported in earlier studies 
among unselected groups of travelers (11, 
12) and 19% among HIV-positive patients 
(3). The low prevalence among patients with 
chronic arthritis should be expected to some 
extent because the patient group may en-
gage in more precautious resulting in less 
health hazardous travel activities owing to 
physical limitations in comparison with oth-
er groups of travelers.
The patients reported a marked tendency in 
discontinuation of treatment with subcutane-
ous biologics when traveling abroad owing to 
logistical challenges in transport and storage 
of medicine. Moreover, a concern was also re-
ported in the questionnaire regarding carrying 
of medicine across the border of the destina-
tion country and anticipation of potential vio-
lation of local custom regulations. This concern 
Table 2. Patient travel activities after initiation of biological treatment.
 n (%)
After having started biologic medicine have you been: 
Travelling abroad less often than before? 42 (15)
Travelling abroad to the same extent as before? 200 (73)
Travelling abroad more often than before? 21 (8)
No answer 10 (4)
Has your rheumatic disease or medical treatment influenced  
your decision to travel abroad? 
Not at all 183 (67)
Yes 57 (21)
Do not know 24 (9)
No answer 9 (3)
Has your medical treatment limited your choice of travel destinations? 
Yes, I have become more cautious 66 (24) 
No 207 (76)
Table 3. Preparation in conjunction with most recent travel abroad.
 n (%)
Among the 203 respondents with a travel history abroad: 
Were you covered by travel insurance? 
Yes 174 (86)
No 29 (14)
Among the 174 respondents covered by travel insurance: 
Did you inform the insurance company about your rheumatic disease and the biological 
treatment? 
Yes 72 (41)
No 102 (59)
If your treatment was changed within two months prior to travel departure,  
did you then make sure that the insurance coverage was still valid? 
Yes, approval was given by the insurance company 34 (20)
No change in treatment  99 (57)
No, I did not 35 (20)
No answer 6 (3) 
Among the 203 respondents with a travel history abroad: 
Did you seek pre-travel advice before departing? 
Yes 52 (26)
No 151 (74)
Among the 52 respondents seeking pre-travel advice: 
Did you inform about your rheumatic disease and the biological treatment? 
Yes 34 (65)
No 18 (35)
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could be addressed and solved by provision of 
a letter to the patient from the clinic physician 
prior to travel departure confirming that the 
hand-carried medicine is approved for treat-
ment.
It was also shown in this study that two-
thirds of the patients did not seek pre-travel 
advice despite receiving immunocompro-
mising treatment, which is associated with 
increased risk of infection. Moreover, lack of 
disclosure of biological treatment proved a 
major issue in this study, both in relation to 
pre-travel advice and travel insurance. It rais-
es concern that one-third (35%) of the pa-
tients who had consulted pre-travel advisor 
did not disclose that they were undergoing 
biological treatment. It is essential for correct 
pre-travel advice and preparation, including 
travel immunization, that the advisor has the 
necessary knowledge about the pre-existing 
medical conditions, e.g., chronic arthritis re-
quiring immunosuppressive biological treat-
ment. 
More than half of the patients with a travel 
insurance had not disclosed the informa-
tion about the chronic arthritis disease and 
treatment to the insurance company. A rheu-
matic disease is a chronic medical condition; 
therefore, the patient must inform the travel 
insurance company in Denmark in case the 
treatment has been changed within the last 
2 months before traveling to obtain full valid 
coverage in relation to the health problems 
occurring abroad. As a result of unstable dis-
ease activity in patients with arthritis, biolog-
ical treatment is frequently adjusted by oral 
drugs or joint injections. Therefore, it is very 
important to remind the patient to inform the 
insurance company about any changes in the 
treatment in case a travel is anticipated within 
the next 2 months.
A limitation of this study is that the data are 
based on patient recall, but we believe the 
recall bias to have limited influence on the 
data.
In conclusion, Danish patients with arthri-
tis treated using biologics travel frequently 
outside of Denmark. Health problems when 
traveling are rarely encountered and are only 
of minor importance. In contrast, discontin-
uation of biological treatment, difficulties in 
transport and storage of medicine, lack of 
pre-travel advice, and likely invalid insurance 
coverage are some of the major challenges, 
which should be addressed proactively by 
the staff in the patient consultation. A patient 
leaflet containing basic information and ad-
vices about traveling with chronic arthritis is 
readily available in the clinic, which could be 
a useful measure to raise awareness among 
the patients about different implications of 
traveling.  
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